A method and apparatus for determining the efficacy of a medicament for the treatment of wounds or scars. The method comprises selecting first and second scarring site portions wherein said first scarring site portion has been treated with said medicament. A pair of images comprising a first image of said first scar...

The invention provides pharmaceutical compositions comprising TGF-ß superfamily members and sugars, the compositions allowing improved recovery and/or increased biological activity of the TGF- ß superfamily member incorporated therein. The invention also relates to uses of sugars to improve the recovery or increase ...

The invention relates to the use of TGF-ß33, or agents having TGF-ß33 activity, to promote epithelial regeneration. Methods of manufacturing medicaments and methods of promoting epithelial regeneration are both provided. In particular, the medicaments and methods of treatment of the invention are applicable to the p...

The invention provides new methods of treatment using anti-scarring agents to inhibit scarring in humans, and also provides anti-scarring agents for new uses in the inhibition of scarring in humans. In a first incidence of treatment an anti-scarring agent is provided to each centimetre of a wound margin or each cent...

There is provided the use of monomeric TGF-βs, or there fragments or derivatives, as medicaments. These medicaments preferably comprise monomeric TGF-β3, or fragments or derivatives thereof. The medicaments provided may be used in the acceleration of wounding and/or the inhibition of scarring, in the promotion of ep...

The invention provides TGF-ß3s, or fragments or derivatives thereof, wherein the alpha- helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-ß3 comprises at least one alpha-helix-stabilising substitution. The invention also provides TGF-ß3s, or fragments or derivatives thereof,...

The present invention concerns a method for folding a Transforming Growth Factor Beta, or a functional analogue thereof, into a dimeric, biologically active form. The method involves adding solubilized, unfolded monomeric growth factor to a solution containing 2-(cylcohexylamino)-ethanesulfonic acid (CHES) or a func...

The invention provides new methods of treatment using TGF- ß 3 to inhibit scarring in humans, and TGF-ß3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment TGF-ß3 is provided to each centimetre of a wound margin or each centimetre of a site at which a wound is to be formed in a f...

The invention provides new methods of treatment using TGF-ß3 to inhibit scarring in humans, and TGF-ß3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment each centimetre of wound margin, or each centimetre of a site at which a wound is to be formed, is provided with between appro...

There is provided the use of mannose-6-phosphate, or a salt, precursor or analogue thereof, for providing and/or maintaining a consistent skin colour, particularly to reducing redness of skin. There is also provided the use of mannose-6-phosphate, or a salt, precursor or analogue thereof, as a skin improvement agent...